terbinafine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2597	91161-71-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: terbinafine terbinol terbinafine hydrochloride terbinafine HCl	A naphthalene derivative that inhibits fungal SQUALENE EPOXIDASE and is used to treat DERMATOMYCOSES of the skin and nails. Molecular weight: 291.44 Formula: C21H25N CLOGP: 5.96 LIPINSKI: 1 HAC: 1 HDO: 0 TPSA: 3.24 ALOGS: -5.60 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

terbinafine
terbinol
terbinafine hydrochloride
terbinafine HCl

A naphthalene derivative that inhibits fungal SQUALENE EPOXIDASE and is used to treat DERMATOMYCOSES of the skin and nails.

Molecular weight: 291.44
Formula: C21H25N
CLOGP: 5.96
LIPINSKI: 1
HAC: 1
HDO: 0
TPSA: 3.24
ALOGS: -5.60
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.25	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	92.64 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	40 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Dec. 30, 1992	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ageusia	361.80	15.83	124	11314	12327	56268302
Acute generalised exanthematous pustulosis	224.58	15.83	82	11356	9787	56270842
Subacute cutaneous lupus erythematosus	183.17	15.83	50	11388	2299	56278330
Dysgeusia	152.44	15.83	98	11340	40817	56239812
Rash pustular	107.13	15.83	43	11395	6620	56274009
Gamma-glutamyltransferase increased	100.24	15.83	68	11370	30937	56249692
Pruritus	93.14	15.83	201	11237	316422	55964207
Aspartate aminotransferase increased	92.00	15.83	98	11340	82504	56198125
Cutaneous lupus erythematosus	87.90	15.83	29	11409	2555	56278074
Blood alkaline phosphatase increased	84.19	15.83	67	11371	38878	56241751
Toxic skin eruption	83.81	15.83	43	11395	11696	56268933
Erythema multiforme	83.03	15.83	40	11398	9514	56271115
Skin exfoliation	76.61	15.83	62	11376	36838	56243791
Alanine aminotransferase increased	75.42	15.83	94	11344	93568	56187061
Pathogen resistance	73.82	15.83	32	11406	5968	56274661
Chromaturia	73.07	15.83	43	11395	15282	56265347
Rash	65.48	15.83	234	11204	492813	55787816
Jaundice	63.39	15.83	49	11389	27245	56253384
Somatic delusion	62.92	15.83	16	11422	556	56280073
Erythema	62.66	15.83	113	11325	155826	56124803
Urticaria	52.04	15.83	100	11338	144576	56136053
Hepatic function abnormal	51.36	15.83	48	11390	34510	56246119
Rash erythematous	50.20	15.83	49	11389	37172	56243457
Rash maculo-papular	46.55	15.83	42	11396	28865	56251764
Lip swelling	43.95	15.83	39	11399	26233	56254396
Anosmia	42.98	15.83	20	11418	4399	56276230
Skin lesion	41.65	15.83	39	11399	28096	56252533
Blood lactate dehydrogenase increased	41.34	15.83	34	11404	20641	56259988
Blood bilirubin increased	39.63	15.83	41	11397	33313	56247316
Hepatitis	39.32	15.83	42	11396	35399	56245230
Onychomycosis	38.21	15.83	21	11417	6551	56274078
Scedosporium infection	36.12	15.83	10	11428	484	56280145
Photosensitivity reaction	35.08	15.83	26	11412	13567	56267062
Rheumatoid arthritis	35.06	15.83	17	11421	382587	55898042
Liver disorder	34.82	15.83	44	11394	44326	56236303
Drug intolerance	34.75	15.83	6	11432	264812	56015817
Pustular psoriasis	33.69	15.83	17	11421	4461	56276168
Oral discomfort	33.54	15.83	21	11417	8334	56272295
Drug resistance	33.37	15.83	30	11408	20512	56260117
Rash pruritic	31.89	15.83	46	11392	52548	56228081
Skin oedema	30.96	15.83	10	11428	823	56279806
Dermatitis bullous	30.31	15.83	19	11419	7554	56273075
Gastrointestinal motility disorder	30.04	15.83	16	11422	4690	56275939
Abnormal faeces	29.85	15.83	16	11422	4752	56275877
Drug eruption	29.40	15.83	31	11407	25732	56254897
Rash papular	28.85	15.83	23	11415	13360	56267269
Dermatitis exfoliative	28.27	15.83	16	11422	5283	56275346
Weight decreased	28.23	15.83	110	11328	240604	56040025
Drug interaction	27.20	15.83	99	11339	209656	56070973
Urine odour abnormal	26.73	15.83	16	11422	5858	56274771
Cholestasis	26.56	15.83	30	11408	26883	56253746
Bilirubin conjugated increased	26.13	15.83	12	11426	2561	56278068
Off label use	25.86	15.83	46	11392	556134	55724495
Tinea infection	25.50	15.83	9	11429	971	56279658
Hepatitis cholestatic	25.44	15.83	16	11422	6398	56274231
Red blood cell count decreased	25.13	15.83	34	11404	36583	56244046
Dermatophytosis	24.74	15.83	6	11432	171	56280458
Face oedema	24.32	15.83	24	11414	18428	56262201
Blood creatine phosphokinase increased	23.99	15.83	29	11409	27923	56252706
Drug-induced liver injury	23.65	15.83	32	11406	34430	56246199
Maternal exposure during pregnancy	23.36	15.83	5	11433	189548	56091081
Erythema nodosum	23.08	15.83	13	11425	4252	56276377
Tinea pedis	22.89	15.83	9	11429	1311	56279318
Rash papulosquamous	22.70	15.83	5	11433	92	56280537
Systemic lupus erythematosus rash	22.65	15.83	10	11428	1946	56278683
Drug ineffective	22.17	15.83	104	11334	918885	55361744
Antinuclear antibody positive	22.08	15.83	15	11423	6826	56273803
Therapeutic product effect decreased	21.86	15.83	4	11434	169448	56111181
Fusarium infection	21.26	15.83	7	11431	612	56280017
Musculoskeletal discomfort	21.09	15.83	21	11417	16297	56264332
Eosinophilia	20.87	15.83	23	11415	20054	56260575
Respiratory gas exchange disorder	20.75	15.83	6	11432	340	56280289
Pythium insidiosum infection	20.43	15.83	3	11435	3	56280626
Rash macular	20.39	15.83	23	11415	20581	56260048
Hypotension	20.22	15.83	13	11425	250495	56030134
Death	19.99	15.83	24	11414	341402	55939227
Linear IgA disease	19.59	15.83	8	11430	1285	56279344
Abortion induced	19.57	15.83	16	11422	9629	56271000
Liver function test abnormal	19.46	15.83	34	11404	45637	56234992
Decreased appetite	19.37	15.83	92	11346	219139	56061490
Pustule	19.15	15.83	8	11430	1361	56279268
Cheilitis	19.12	15.83	11	11427	3746	56276883
Drug reaction with eosinophilia and systemic symptoms	19.09	15.83	27	11411	30277	56250352
Swollen tongue	19.07	15.83	27	11411	30297	56250332
Hepatitis toxic	18.74	15.83	10	11428	2942	56277687
Fungal skin infection	18.33	15.83	11	11427	4047	56276582
Infusion related reaction	18.04	15.83	10	11428	208921	56071708
Pityriasis rosea	17.94	15.83	4	11434	78	56280551
Depression	17.70	15.83	78	11360	180039	56100590
Toxicity to various agents	17.65	15.83	12	11426	224552	56056077
Fundoscopy abnormal	17.49	15.83	3	11435	13	56280616
Glossodynia	16.89	15.83	5	11433	152453	56128176
Myalgia	16.82	15.83	62	11376	131963	56148666
Pneumonia respiratory syncytial viral	16.66	15.83	6	11432	686	56279943
Product use issue	15.92	15.83	9	11429	186032	56094597

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pathogen resistance	186.85	13.95	82	11663	8619	31676980
Aspartate aminotransferase increased	119.28	13.95	131	11614	62588	31623011
Gamma-glutamyltransferase increased	106.98	13.95	86	11659	27739	31657860
Ageusia	97.98	13.95	54	11691	9277	31676322
Drug resistance	95.53	13.95	75	11670	23378	31662221
Alanine aminotransferase increased	94.65	13.95	127	11618	74529	31611070
Chromaturia	80.32	13.95	54	11691	13244	31672355
Jaundice	76.97	13.95	74	11671	30213	31655386
Onychomycosis	75.35	13.95	29	11716	2177	31683422
Blood alkaline phosphatase increased	74.91	13.95	72	11673	29381	31656218
Acute generalised exanthematous pustulosis	71.91	13.95	38	11707	6002	31679597
Blood creatine phosphokinase increased	71.74	13.95	83	11662	41891	31643708
Scedosporium infection	62.90	13.95	20	11725	850	31684749
Symmetrical drug-related intertriginous and flexural exanthema	54.49	13.95	14	11731	272	31685327
Rash	54.43	13.95	181	11564	201305	31484294
Pruritus	50.67	13.95	130	11615	125037	31560562
Diaphragmatic spasm	50.33	13.95	11	11734	102	31685497
Faecal volume decreased	48.88	13.95	11	11734	118	31685481
Death	48.22	13.95	38	11707	360531	31325068
Liver disorder	47.83	13.95	57	11688	29650	31655949
Rash pustular	44.80	13.95	26	11719	4923	31680676
Blood lactate dehydrogenase increased	43.01	13.95	45	11700	20294	31665305
Liver function test abnormal	42.99	13.95	54	11691	29638	31655961
Rash erythematous	39.06	13.95	45	11700	22582	31663017
Blood bilirubin increased	38.80	13.95	56	11689	35080	31650519
Skin exfoliation	37.10	13.95	45	11700	23829	31661770
Treatment failure	36.55	13.95	59	11686	40733	31644866
Epstein-Barr virus antibody positive	35.28	13.95	10	11735	285	31685314
Hypotension	35.08	13.95	16	11729	204602	31480997
Hepatic lesion	34.34	13.95	19	11726	3284	31682315
Impetigo	33.87	13.95	13	11732	968	31684631
Hepatic function abnormal	33.41	13.95	57	11688	41165	31644434
Erythema nodosum	31.94	13.95	13	11732	1130	31684469
Swelling of eyelid	31.40	13.95	12	11733	883	31684716
Toxicity to various agents	31.40	13.95	14	11731	181473	31504126
Trichophytosis	30.87	13.95	9	11736	284	31685315
Eczema	28.88	13.95	32	11713	15385	31670214
Erythema	27.94	13.95	79	11666	80326	31605273
Abscess sweat gland	27.60	13.95	4	11741	0	31685599
Erythema multiforme	26.93	13.95	23	11722	8048	31677551
Off label use	26.32	13.95	56	11689	347218	31338381
Cutaneous lupus erythematosus	26.06	13.95	10	11735	744	31684855
Rosacea	25.98	13.95	11	11734	1056	31684543
Urticaria	25.59	13.95	62	11683	57455	31628144
Tongue discomfort	25.00	13.95	9	11736	560	31685039
Tinea pedis	24.81	13.95	11	11734	1181	31684418
Drug-induced liver injury	24.26	13.95	37	11708	24326	31661273
Antinuclear antibody positive	23.48	13.95	11	11734	1342	31684257
Dysgeusia	22.47	13.95	35	11710	23431	31662168
Choluria	21.76	13.95	6	11739	154	31685445
Erythrodermic psoriasis	21.52	13.95	9	11736	838	31684761
Myalgia	21.29	13.95	70	11675	77188	31608411
Deficiency of bile secretion	21.17	13.95	4	11741	16	31685583
Hepatitis cholestatic	21.10	13.95	19	11726	7127	31678472
Myoglobin urine present	21.10	13.95	6	11739	173	31685426
Cholestasis	20.74	13.95	35	11710	25040	31660559
CARD9 deficiency	20.45	13.95	4	11741	20	31685579
Drug eruption	20.08	13.95	29	11716	18158	31667441
Hairy cell leukaemia	19.98	13.95	5	11740	87	31685512
Blister	19.73	13.95	31	11714	20905	31664694
Biliary obstruction	19.70	13.95	12	11733	2481	31683118
Lymphocyte stimulation test positive	19.67	13.95	8	11737	694	31684905
Skin warm	19.29	13.95	11	11734	2015	31683584
Rhabdomyolysis	18.78	13.95	59	11686	63522	31622077
Dermatitis exfoliative	18.66	13.95	17	11728	6475	31679124
Pythium insidiosum infection	18.63	13.95	3	11742	3	31685596
Hodgkin's disease	18.04	13.95	8	11737	860	31684739
Discomfort	17.94	13.95	26	11719	16330	31669269
Completed suicide	17.55	13.95	6	11739	91508	31594091
Dermatitis contact	17.27	13.95	12	11733	3098	31682501
Benign breast neoplasm	17.09	13.95	3	11742	7	31685592
Neutrophil percentage decreased	17.02	13.95	6	11739	351	31685248
Product substitution issue	16.68	13.95	19	11726	9413	31676186
Pneumonia	16.64	13.95	66	11679	335246	31350353
Pityriasis rosea	16.60	13.95	4	11741	59	31685540
Vitamin E deficiency	16.55	13.95	3	11742	9	31685590
Chromoblastomycosis	16.48	13.95	4	11741	61	31685538
Dermatitis	16.44	13.95	18	11727	8538	31677061
Product dispensing error	16.29	13.95	15	11730	5789	31679810
Periorbital oedema	16.09	13.95	12	11733	3459	31682140
Malaise	15.99	13.95	112	11633	168399	31517200
Eyelid pain	15.85	13.95	4	11741	72	31685527
Intertrigo	15.85	13.95	5	11740	207	31685392
Skin lesion	15.81	13.95	27	11718	19500	31666099
Prostatic haemorrhage	15.18	13.95	5	11740	238	31685361
Nail discolouration	14.88	13.95	7	11738	862	31684737
Neuropsychiatric symptoms	14.78	13.95	6	11739	518	31685081
Skin plaque	14.55	13.95	12	11733	4003	31681596
Hepatocellular carcinoma	14.41	13.95	17	11728	8739	31676860
Hepatic enzyme increased	14.17	13.95	37	11708	35871	31649728
Seborrhoeic dermatitis	14.04	13.95	8	11737	1462	31684137

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ageusia	316.21	12.83	129	20103	14733	70893479
Pathogen resistance	261.26	12.83	109	20123	13170	70895042
Acute generalised exanthematous pustulosis	242.51	12.83	108	20124	15289	70892923
Aspartate aminotransferase increased	165.06	12.83	192	20040	126786	70781426
Subacute cutaneous lupus erythematosus	163.03	12.83	53	20179	3160	70905052
Gamma-glutamyltransferase increased	155.09	12.83	123	20109	50562	70857650
Chromaturia	145.35	12.83	88	20144	23440	70884772
Alanine aminotransferase increased	139.08	12.83	190	20042	147290	70760922
Rash pustular	133.10	12.83	63	20169	10245	70897967
Drug resistance	130.57	12.83	99	20133	38091	70870121
Blood alkaline phosphatase increased	123.88	12.83	115	20117	58406	70849806
Jaundice	118.89	12.83	105	20127	50003	70858209
Pruritus	112.77	12.83	281	19951	345279	70562933
Rash	100.04	12.83	346	19886	510216	70397996
Dysgeusia	98.47	12.83	94	20138	49408	70858804
Skin exfoliation	96.09	12.83	92	20140	48534	70859678
Scedosporium infection	95.61	12.83	29	20203	1375	70906837
Cutaneous lupus erythematosus	93.80	12.83	34	20198	2814	70905398
Blood creatine phosphokinase increased	88.61	12.83	98	20134	61165	70847047
Rash erythematous	84.05	12.83	88	20144	51630	70856582
Onychomycosis	82.47	12.83	40	20192	6861	70901351
Erythema multiforme	79.91	12.83	53	20179	16511	70891701
Toxic skin eruption	79.56	12.83	57	20175	20105	70888107
Erythema	69.96	12.83	167	20065	199396	70708816
Blood lactate dehydrogenase increased	64.77	12.83	64	20168	35063	70873149
Somatic delusion	63.23	12.83	18	20214	682	70907530
Hepatic function abnormal	60.10	12.83	85	20147	67911	70840301
Urticaria	59.90	12.83	139	20093	162910	70745302
Blood bilirubin increased	59.14	12.83	79	20153	59822	70848390
Liver function test abnormal	56.37	12.83	78	20154	61068	70847144
Hypotension	53.88	12.83	24	20208	404357	70503855
Liver disorder	52.99	12.83	76	20156	61492	70846720
Diaphragmatic spasm	52.81	12.83	11	20221	106	70908106
Toxicity to various agents	50.41	12.83	23	20209	382149	70526063
Symmetrical drug-related intertriginous and flexural exanthema	49.82	12.83	15	20217	693	70907519
Faecal volume decreased	48.22	12.83	11	20221	167	70908045
Skin lesion	46.31	12.83	56	20176	38404	70869808
Completed suicide	44.60	12.83	6	20226	227129	70681083
Cholestasis	44.01	12.83	61	20171	47811	70860401
Off label use	43.53	12.83	92	20140	742968	70165244
Tinea pedis	43.08	12.83	18	20214	2178	70906034
Death	42.31	12.83	50	20182	510011	70398201
Pustular psoriasis	41.13	12.83	22	20210	4628	70903584
Lip swelling	40.05	12.83	49	20183	34005	70874207
Rheumatoid arthritis	39.34	12.83	17	20215	291788	70616424
Photosensitivity reaction	38.96	12.83	37	20195	19303	70888909
Drug eruption	38.84	12.83	52	20180	39444	70868768
Dermatitis exfoliative	37.48	12.83	28	20204	10523	70897689
Anosmia	37.38	12.83	21	20211	4862	70903350
Pythium insidiosum infection	37.09	12.83	6	20226	10	70908202
Trichophytosis	35.73	12.83	10	20222	356	70907856
Oral discomfort	34.91	12.83	25	20207	8806	70899406
Drug-induced liver injury	34.02	12.83	59	20173	56054	70852158
Antinuclear antibody positive	33.28	12.83	22	20210	6811	70901401
Rash maculo-papular	33.10	12.83	55	20177	50490	70857722
Hepatic lesion	33.00	12.83	21	20211	6096	70902116
Myalgia	32.87	12.83	114	20118	167778	70740434
Pityriasis rosea	32.31	12.83	8	20224	175	70908037
Drug intolerance	32.29	12.83	12	20220	225675	70682537
Urine odour abnormal	32.01	12.83	20	20212	5623	70902589
Skin oedema	31.27	12.83	13	20219	1553	70906659
Drug abuse	31.12	12.83	3	20229	147253	70760959
Eczema	30.98	12.83	43	20189	33738	70874474
Hepatitis cholestatic	30.96	12.83	27	20205	12623	70895589
Erythema nodosum	30.89	12.83	18	20214	4463	70903749
Epstein-Barr virus antibody positive	30.45	12.83	10	20222	615	70907597
Dermatophytosis	28.96	12.83	9	20223	463	70907749
Impetigo	28.59	12.83	13	20219	1927	70906285
Periorbital oedema	28.44	12.83	21	20211	7754	70900458
Tinea infection	28.36	12.83	11	20221	1098	70907114
Hepatitis	27.03	12.83	50	20182	49930	70858282
Dermatitis bullous	26.83	12.83	25	20207	12732	70895480
Red blood cell count decreased	26.74	12.83	51	20181	52110	70856102
Skin plaque	26.23	12.83	22	20210	9761	70898451
Swelling of eyelid	25.85	12.83	14	20218	3018	70905194
Rash macular	25.68	12.83	34	20198	25510	70882702
Contraindicated product administered	25.38	12.83	4	20228	134608	70773604
Hepatitis toxic	25.34	12.83	16	20216	4583	70903629
Decreased appetite	25.29	12.83	161	20071	304619	70603593
Rhabdomyolysis	25.15	12.83	72	20160	95688	70812524
Abnormal faeces	24.59	12.83	18	20214	6555	70901657
Dermatitis	24.56	12.83	29	20203	19388	70888824
Systemic lupus erythematosus rash	24.29	12.83	11	20221	1616	70906596
Face oedema	24.05	12.83	33	20199	25606	70882606
Rash pruritic	23.42	12.83	54	20178	62937	70845275
Blister	23.01	12.83	72	20160	100454	70807758
Maternal exposure during pregnancy	22.74	12.83	3	20229	115342	70792870
Gastrointestinal motility disorder	22.56	12.83	16	20216	5550	70902662
Abscess sweat gland	22.22	12.83	4	20228	16	70908196
Hairy cell leukaemia	21.85	12.83	5	20227	77	70908135
Antiphospholipid antibodies positive	21.71	12.83	8	20224	693	70907519
CARD9 deficiency	21.49	12.83	4	20228	20	70908192
Lymphocyte stimulation test positive	21.47	12.83	9	20223	1098	70907114
Pustule	21.33	12.83	10	20222	1589	70906623
Neutrophil percentage decreased	21.10	12.83	8	20224	751	70907461
Drug reaction with eosinophilia and systemic symptoms	20.77	12.83	49	20183	57964	70850248
Fungal skin infection	20.51	12.83	15	20217	5457	70902755
Infusion related reaction	20.24	12.83	16	20216	197518	70710694
Hodgkin's disease	20.01	12.83	8	20224	865	70907347
Pneumonia	19.89	12.83	95	20137	596137	70312075
Therapeutic product effect decreased	19.79	12.83	8	20224	143010	70765202
Eosinophil count increased	19.70	12.83	23	20209	15199	70893013
Rash papular	19.49	12.83	25	20207	18185	70890027
Rash papulosquamous	19.26	12.83	5	20227	133	70908079
Faeces pale	19.10	12.83	11	20221	2669	70905543
Prostatic haemorrhage	18.69	12.83	5	20227	150	70908062
Choluria	18.58	12.83	6	20226	350	70907862
Neuropsychiatric symptoms	18.54	12.83	8	20224	1048	70907164
Stevens-Johnson syndrome	18.27	12.83	35	20197	35872	70872340
Erythrodermic psoriasis	17.86	12.83	9	20223	1675	70906537
Anal haemorrhage	17.84	12.83	12	20220	3824	70904388
Intentional product use issue	17.84	12.83	6	20226	120136	70788076
Biliary obstruction	17.31	12.83	12	20220	4015	70904197
Weight decreased	17.17	12.83	149	20083	310339	70597873
Skin warm	17.06	12.83	14	20218	6027	70902185
Septal panniculitis	17.05	12.83	4	20228	69	70908143
Neutrophilia	16.85	12.83	15	20217	7206	70901006
Musculoskeletal discomfort	16.80	12.83	23	20209	17809	70890403
Seborrhoeic dermatitis	16.79	12.83	9	20223	1901	70906311
Macule	16.75	12.83	10	20222	2593	70905619
Treatment failure	16.46	12.83	83	20149	144059	70764153
Chromoblastomycosis	16.18	12.83	4	20228	87	70908125
Malaise	15.90	12.83	191	20041	432741	70475471
Rosacea	15.84	12.83	11	20221	3690	70904522
Vitamin E deficiency	15.66	12.83	3	20229	18	70908194
Tongue discomfort	15.47	12.83	9	20223	2226	70905986
Mean cell volume abnormal	15.18	12.83	6	20226	630	70907582
Erectile dysfunction	15.11	12.83	19	20213	13543	70894669
Cardio-respiratory arrest	14.99	12.83	5	20227	100672	70807540
Intertrigo	14.90	12.83	6	20226	661	70907551
Tinea versicolour	14.90	12.83	5	20227	329	70907883
Dermatitis contact	14.78	12.83	16	20216	9733	70898479
Fusarium infection	14.77	12.83	8	20224	1724	70906488
Eye swelling	14.53	12.83	25	20207	23589	70884623
Intentional overdose	14.46	12.83	5	20227	98430	70809782
Myoglobin urine present	14.35	12.83	6	20226	727	70907485
Hypokalaemia	14.24	12.83	10	20222	131178	70777034
Respiratory gas exchange disorder	14.08	12.83	6	20226	762	70907450
Erythema annulare	14.07	12.83	4	20228	151	70908061
Dehydration	14.03	12.83	27	20205	226115	70682097
Laryngeal pain	13.56	12.83	12	20220	5716	70902496
Sinusitis	13.55	12.83	17	20215	169178	70739034
Urinary tract infection	13.51	12.83	32	20200	248737	70659475
Product use issue	13.47	12.83	19	20213	179918	70728294
Depression	13.44	12.83	100	20132	198874	70709338
Drug interaction	13.44	12.83	167	20065	381274	70526938
Deficiency of bile secretion	13.38	12.83	3	20229	42	70908170
Prothrombin time shortened	13.19	12.83	9	20223	2933	70905279
Pulmonary embolism	13.18	12.83	15	20217	155852	70752360
Arthropathy	13.18	12.83	14	20218	150043	70758169
Febrile neutropenia	13.02	12.83	24	20208	204294	70703918
Lower respiratory tract infection	12.87	12.83	8	20224	111905	70796307

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D01AE15	DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Other antifungals for topical use
ATC	D01BA02	DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR SYSTEMIC USE Antifungals for systemic use
FDA CS	M0000751	Allylamine
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000935	Antifungal Agents
MeSH PA	D004791	Enzyme Inhibitors
CHEBI has role	CHEBI:50183	P450 inhibitors
CHEBI has role	CHEBI:59285	squalene monooxygenase inhibitors
CHEBI has role	CHEBI:83317	sterol biosynthesis inhibitors
FDA EPC	N0000175874	Allylamine Antifungal

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Tinea capitis	indication	5441008
Tinea pedis	indication	6020002	DOID:12403
Pityriasis versicolor	indication	56454009	DOID:9060
Tinea corporis	indication	84849002
Tinea cruris	indication	399029005
Onychomycosis due to dermatophyte	indication	402134005
Onychomycosis of fingernails	indication	403058003
Onychomycosis of toenails	indication	403059006
Candidiasis of skin	off-label use	49883006
Chromoblastomycosis	off-label use	187079000
Alcoholism	contraindication	7200002
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Otitis externa caused by yeast, Malassezia pachydermatis	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Osurnia	Dechra, Ltd.	3
CLARO	Elanco US Inc.	3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.02	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.63	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.39	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	6.70	DRUG MATRIX
Squalene monooxygenase	Enzyme	Q14534	ERG1_HUMAN		Ki	7.52	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.67	DRUG MATRIX
Squalene epoxidase	Enzyme		Q4JEY0_TRIRU	INHIBITOR			CHEMBL	CHEMBL
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	7.66	DRUG MATRIX
Squalene monooxygenase	Enzyme		ERG1_RAT		IC50	4.03	CHEMBL

External reference:

ID	Source
4023600	VUID
N0000021605	NUI
D02219	KEGG_DRUG
78628-80-5	SECONDARY_CAS_RN
4020792	VANDF
4023600	VANDF
C0076110	UMLSCUI
CHEBI:9448	CHEBI
CHEMBL822	ChEMBL_ID
DB00857	DRUGBANK_ID
CHEMBL1200832	ChEMBL_ID
D000077291	MESH_DESCRIPTOR_UI
1549008	PUBCHEM_CID
5657	INN_ID
G7RIW8S0XP	UNII
235838	RXNORM
116863	MMSL
24434	MMSL
5547	MMSL
d04012	MMSL
004051	NDDF
004052	NDDF
108925005	SNOMEDCT_US
108927002	SNOMEDCT_US
373450007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
LamisilAT	HUMAN OTC DRUG LABEL	1	0067-3998	CREAM	10 mg	TOPICAL	NDA	13 sections
LamisilAT Jock Itch	HUMAN OTC DRUG LABEL	1	0067-3999	CREAM	10 mg	TOPICAL	NDA	13 sections
LAMISILAT	HUMAN OTC DRUG LABEL	1	0067-6296	AEROSOL, SPRAY	0.84 g	TOPICAL	NDA	13 sections
LAMISILAT	HUMAN OTC DRUG LABEL	1	0067-6297	AEROSOL, SPRAY	0.84 g	TOPICAL	NDA	13 sections
Lamisil AT	HUMAN OTC DRUG LABEL	1	0067-8100	CREAM	1 g	TOPICAL	ANDA	14 sections
Lamisil ATfor Jock Itch	HUMAN OTC DRUG LABEL	1	0067-8114	CREAM	1 g	TOPICAL	ANDA	14 sections
Walgreens Athletes Foot	HUMAN OTC DRUG LABEL	1	0363-2080	CREAM	1 g	TOPICAL	ANDA	14 sections
Terbinafine Hydrochloride	HUMAN OTC DRUG LABEL	1	0363-2083	CREAM	1 g	TOPICAL	ANDA	14 sections
Athletes Foot	HUMAN OTC DRUG LABEL	1	11673-080	CREAM	1 g	TOPICAL	ANDA	14 sections
athletes foot	HUMAN OTC DRUG LABEL	1	11673-401	CREAM	10 mg	TOPICAL	NDA	7 sections
Athletes Foot	HUMAN OTC DRUG LABEL	1	11822-0080	CREAM	1 g	TOPICAL	ANDA	14 sections
Terbinafine	Human Prescription Drug Label	1	16714-795	TABLET	250 mg	ORAL	ANDA	27 sections
Athletes Foot	HUMAN OTC DRUG LABEL	1	21130-080	CREAM	1 g	TOPICAL	ANDA	13 sections
Terbinafine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	21695-630	TABLET	250 mg	ORAL	ANDA	19 sections
Good Neighbor Pharmacy	HUMAN OTC DRUG LABEL	1	24385-524	CREAM	1 g	TOPICAL	ANDA	14 sections
Kroger Antifungal	HUMAN OTC DRUG LABEL	1	30142-080	CREAM	1 g	TOPICAL	ANDA	14 sections
Terbinafine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	31722-209	TABLET	250 1	ORAL	ANDA	26 sections
Athletes Foot	HUMAN OTC DRUG LABEL	1	36800-080	CREAM	1 g	TOPICAL	ANDA	14 sections
Shopko Athletes Foot	HUMAN OTC DRUG LABEL	1	37012-080	CREAM	1 g	TOPICAL	ANDA	14 sections
Athletes Foot	HUMAN OTC DRUG LABEL	1	37808-080	CREAM	1 g	TOPICAL	ANDA	14 sections
athletes foot	HUMAN OTC DRUG LABEL	1	41163-080	CREAM	1 g	TOPICAL	ANDA	14 sections
ShopRite	HUMAN OTC DRUG LABEL	1	41190-083	CREAM	1 g	TOPICAL	ANDA	14 sections
Antifungal	HUMAN OTC DRUG LABEL	1	41250-080	CREAM	1 g	TOPICAL	ANDA	14 sections
Antifungal Foot	HUMAN OTC DRUG LABEL	1	41520-080	CREAM	1 g	TOPICAL	ANDA	14 sections
terbinafine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42043-410	TABLET	250 mg	ORAL	ANDA	20 sections
Terbinafine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43063-598	TABLET	250 mg	ORAL	ANDA	31 sections
Terbinafine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43063-906	TABLET	250 mg	ORAL	ANDA	33 sections
Terbinafine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43063-906	TABLET	250 mg	ORAL	ANDA	33 sections
Terbinafine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43353-893	TABLET	250 mg	ORAL	ANDA	31 sections
equate Athletes Foot	HUMAN OTC DRUG LABEL	1	49035-080	CREAM	1 g	TOPICAL	ANDA	14 sections